Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | = 0.14 uM | Cytotoxicity against human Col2 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 0.14 uM | Cytotoxicity against human Col2 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 1.96 uM | Cytotoxicity against human SNU638 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 2.64 uM | Cytotoxicity against human HL60 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 2.64 uM | Cytotoxicity against human HL60 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 10.38 uM | Cytotoxicity against human HT1080 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 10.38 uM | Cytotoxicity against human HT1080 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 13.97 uM | Cytotoxicity against human A549 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
IC50 (ADMET) | = 13.97 uM | Cytotoxicity against human A549 cells after 3 days by SRB assay | ChEMBL. | 17035025 |
Inhibition (binding) | = 80 % | Inhibition of human recombinant topoisomerase 2-mediated KDNA decatenation activity at 200 uM relative to control | ChEMBL. | 17035025 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 17035025 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.